№ lp_1_2_20762
File format: docx
Character count: 55117
File size: 108 KB
Year:
2015
Region / city:
Australia
Theme:
Hypercholesterolemia treatment
Document type:
Pharmaceutical submission
Organization / institution:
Amgen Australia Pty Limited
Author:
Amgen Australia Pty Limited
Target audience:
Healthcare professionals
Period of validity:
Ongoing
Approval date:
4 December 2015
Date of amendments:
December 2022
Context:
Submission to modify existing PBS listings for evolocumab for the treatment of different types of hypercholesterolemia, including changes to prescription requirements and treatment duration.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Topic:
Lipid disorders, Cardiovascular Risk
Document Type:
Medical guideline
Target Audience:
Medical professionals, healthcare providers
Year:
2023
Region:
Australia
Topic:
Hypercholesterolaemia treatment
Document type:
Drug utilisation analysis
Organization:
Department of Health and Aged Care; Services Australia
Author:
Drug Utilisation Sub-Committee (DUSC)
Target audience:
Healthcare policymakers, clinicians
PBS listing date:
1 December 2016
Data sources:
PBS and Authorities databases
Indications:
Homozygous familial hypercholesterolaemia, heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia
Number of patients treated (2021):
6,119
Number of prescriptions supplied (2021):
48,483
Therapeutic class:
PCSK9 inhibitor
Year:
2026
Region / City:
Australia
Topic:
Pharmaceutical Submission
Document Type:
Application
Institution / Organization:
Amgen Australia Pty Ltd
Author:
Not specified
Target Audience:
Not specified
Period of Effect:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United States
Topic:
Genetic Conditions, Familial Hypercholesterolemia
Document Type:
Template Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Family members of individuals diagnosed with FH
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Theme:
Genetics, Medical Diagnostics
Document type:
Educational activity
Target audience:
Students, Educators
Year:
2023
Region / City:
Denmark
Topic:
Familial Hypercholesterolemia, Lipid Profiles, Cardiovascular Risk
Document Type:
Supplementary Data / Research Tables
Institution:
Danish National Patient Registry, Danish Familial Hypercholesterolemia Registry
Authors:
Hedegaard BS, Bork CS, Kanstrup HL, Besseling J, Visseren F, et al.
Target Audience:
Researchers and clinicians in cardiology and genetics
Data Collection Period:
Up to 2023
Methods:
Clinical data validation, genetic testing, lipid-lowering treatment assessment
Abbreviations Used:
LDL-C, Lp(a), FH, DLCN, DNPR, LDLR, ApoB, PCSK9
Data Validity:
Positive predictive values and sensitivity for DLCN components
Follow-up:
6±2 months post-diagnosis
Genetic Analysis:
Pathogenic variants in LDLR, ApoB, PCSK9
Year:
2023
Region / City:
Australia
Theme:
Medicine, Oncology
Document Type:
Submission Report
Organization / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
JANSSEN-CILAG PTY LTD
Target Audience:
Healthcare professionals, regulators
Period of Validity:
Ongoing
Approval Date:
28 March 2023
Modification Date:
December 2022
Year:
2025
Region / City:
Brooklyn, New York
Topic:
Urban Planning, Public Land Acquisition, Parks and Recreation
Document Type:
Resolution
Organization / Institution:
The Council of the City of New York
Author:
Council Members Salamanca and Hanks
Target Audience:
City Officials, Urban Planners, Residents of Brooklyn
Action Period:
2025-2035
Approval Date:
December 4, 2025
Date of Amendments:
None
Organization:
GBR International 420 Class Association
Meeting type:
Monthly committee meeting
Date:
7 October 2025
Format:
Online meeting via Microsoft Teams
Chair:
Piers Shepherd
Attendees:
Piers Shepherd, Alice Bailey, Mark Upton Brown, Steve Smith, Sam Sandow, Mark Howard, David Fletcher, David Davies, Vicky Skelding, Clare Rogers, Zac Shepherd, Arthur Greaves, Charlie Howard
Invitees:
Sharon Davidson-Guild
Apologies:
Clare Upton Brown, Harry George, Hennie Burlton, Laragh Epstein, Isla Fletcher, Rosie O’Donnell
Key topics:
governance, events calendar, training programmes, marketing and sponsorship, international participation, finance, technology use
Decisions and actions:
multiple actions assigned to named committee members across events, training, policy, sponsorship, and administration
Document type:
Meeting minutes
Trial Host:
PATRICIA GRASSEY
Trial Host Contact Info:
Patricia Grassey, [email protected]
Note:
NW3 - Friday, March 27, 2026
Certifying Official:
Sarah Woodruff
Judges:
Linda Murphy and Sandy Banthem
NW3:
$215 per dog and handler team
Elite:
$225 per dog and handler team
Elite-S:
$150 per dog and handler team
L3I:
$150 per dog and handler team
Elite-Select:
20 entries
Year:
2026
Region / City:
Kennett Square, PA
Theme:
Dog trial event
Document Type:
Event entry information
Organ / Institution:
NACSW
Author:
Patricia Grassey
Target Audience:
Participants in dog trials
Period of Validity:
March 27-29, 2026
Date of Approval:
February 9, 2026
Date of Changes:
February 9, 2026
Year:
2019
Region / City:
Missouri
Theme:
Civil Rights Law
Document Type:
Course Syllabus
Institution:
Missouri Western State University
Author:
David Tushaus
Target Audience:
University students
Period of Validity:
Spring 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
Australia
Topic:
Pharmaceutical Submission
Document Type:
Application
Institution / Organization:
Amgen Australia Pty Ltd
Author:
Not specified
Target Audience:
Not specified
Period of Effect:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018
Region / City:
Abuja
Field of Study:
Psychology
Document Type:
Exam Paper
Institution:
National Open University of Nigeria
Author:
Faculty of Education
Target Audience:
Students of Social Psychology
Period of Validity:
2018
Date of Approval:
2018
Date of Modifications:
N/A
Context:
An examination paper for a course on Social Psychology of Instruction, consisting of multiple questions focused on psychology concepts and theories.